Philipp le Coutre
Philipp le Coutre
Professor für Innere Medizin, Charité, Humboldt University, Berlin
Verified email at charite.de
Title
Cited by
Cited by
Year
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia
G Saglio, DW Kim, S Issaragrisil, P Le Coutre, G Etienne, C Lobo, ...
New England Journal of Medicine 362 (24), 2251-2259, 2010
18102010
A phase 2 trial of ponatinib in Philadelphia chromosome–positive leukemias
JE Cortes, DW Kim, J Pinilla-Ibarz, P Le Coutre, R Paquette, C Chuah, ...
New England Journal of Medicine 369 (19), 1783-1796, 2013
9452013
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia …
HM Kantarjian, F Giles, N Gattermann, K Bhalla, G Alimena, F Palandri, ...
Blood, The Journal of the American Society of Hematology 110 (10), 3540-3546, 2007
8802007
Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification
P le Coutre, E Tassi, M Varella-Garcia, R Barni, L Mologni, G Cabrita, ...
Blood, The Journal of the American Society of Hematology 95 (5), 1758-1766, 2000
6672000
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
A Hochhaus, G Saglio, TP Hughes, RA Larson, DW Kim, S Issaragrisil, ...
Leukemia 30 (5), 1044-1054, 2016
5812016
In Vivo Eradication of Human BCR/ABL-Positive Leukemia Cells With an ABL Kinase Inhibitor
P Le Coutre, L Mologni, L Cleris, E Marchesi, E Buchdunger, R Giardini, ...
Journal of the National Cancer Institute 91 (2), 163-168, 1999
4691999
Role of α1 Acid Glycoprotein in the In Vivo Resistance of Human BCR-ABL+ Leukemic Cells to the Abl Inhibitor STI571
C Gambacorti-Passerini, R Barni, P Le Coutre, M Zucchetti, G Cabrita, ...
Journal of the National Cancer Institute 92 (20), 1641-1650, 2000
4622000
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results
HM Kantarjian, FJ Giles, KN Bhalla, J Pinilla-Ibarz, RA Larson, ...
Blood, The Journal of the American Society of Hematology 117 (4), 1141-1145, 2011
4532011
Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib
C Gambacorti-Passerini, L Antolini, FX Mahon, F Guilhot, M Deininger, ...
Journal of the National Cancer Institute 103 (7), 553-561, 2011
4322011
Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis
C Gambacorti-Passerini, P Le Coutre, L Mologni, M Fanelli, C Bertazzoli, ...
Blood Cells, Molecules, and Diseases 23 (3), 380-394, 1997
4281997
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or-intolerant accelerated-phase chronic …
P Le Coutre, OG Ottmann, F Giles, DW Kim, J Cortes, N Gattermann, ...
Blood, The Journal of the American Society of Hematology 111 (4), 1834-1839, 2008
3652008
European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia
JL Steegmann, M Baccarani, M Breccia, LF Casado, V García-Gutiérrez, ...
Leukemia 30 (8), 1648-1671, 2016
3332016
Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial
JE Cortes, C Gambacorti-Passerini, MW Deininger, MJ Mauro, C Chuah, ...
Journal of Clinical Oncology 36 (3), 231, 2018
2502018
Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors
P Valent, E Hadzijusufovic, GH Schernthaner, D Wolf, D Rea, P le Coutre
Blood, The Journal of the American Society of Hematology 125 (6), 901-906, 2015
2472015
Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib
TD Kim, D Rea, M Schwarz, P Grille, FE Nicolini, G Rosti, L Levato, ...
Leukemia 27 (6), 1316-1321, 2013
2442013
Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study
FJ Giles, PD Le Coutre, J Pinilla-Ibarz, RA Larson, N Gattermann, ...
Leukemia 27 (1), 107-112, 2013
2262013
Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial
JE Cortes, DW Kim, J Pinilla-Ibarz, PD le Coutre, R Paquette, C Chuah, ...
Blood, The Journal of the American Society of Hematology 132 (4), 393-404, 2018
2162018
Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy …
FJ Giles, MJ Mauro, F Hong, CE Ortmann, C McNeill, RC Woodman, ...
Leukemia 27 (6), 1310-1315, 2013
2112013
Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study
A Hochhaus, T Masszi, FJ Giles, JP Radich, DM Ross, MTG Casares, ...
Leukemia 31 (7), 1525-1531, 2017
2072017
Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study
NP Shah, F Guilhot, JE Cortes, CA Schiffer, P Le Coutre, TH Brümmendorf, ...
Blood, The Journal of the American Society of Hematology 123 (15), 2317-2324, 2014
1842014
The system can't perform the operation now. Try again later.
Articles 1–20